Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01987830 · ClinicalTrials.gov registry record · NA
Bevacizumab w / Temozolomide PET & Vascular MRI For GBM
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT01987830: Completed NA study, sponsored by Massachusetts General Hospital.
NCT01987830 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01987830, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
This research study is exploring how the blood vessels in the participant's tumor change from treatment with bevacizumab, and how these changes affect the way their tumor absorbs temozolomide (TMZ). The pilot part of this study is to evaluate the use of \[11C\] temozolomide PET (TMZ-PET) scans and MRI scans to tell investigators more about how standard treatment with bevacizumab affects the blood vessels in the participant's tumor, and how these changes affect the way the participant's tumor absorbs temozolomide. "Investigational" means that the role of TMZ-PET scans is still being studied and that research doctors are trying to find out more about it. Bevacizumab is approved by the U.S. Food and Drug Administration for use in people with the participant's type of cancer. It works by blocking signals on a specific protein called vascular endothelial growth hormone (VEGF), which plays a role in promoting the growth of spread of tumor blood vessels. Bevacizumab is an "anti-VEGF' agent because it is designed to slow the growth of the participant's cancer. Since anti-VEGF agents also affect normal blood vessels in the brain, they can inhibit the way other drugs used in combination with bevacizumab are delivered to the tumor. Researchers are looking for how bevacizumab affects delivery of chemotherapy, in this case temozolomide. In PET scans, a radioactive substance is injected into the body. The scanning machine finds the radioactive substance, which tends to go to cancer cells. For the PET scans in this research study, the investigators are using a radioactive substance called \[11C\] temozolomide, which is chemically identical to the prescription drug TMZ. TMZ is FDA approved as a chemotherapeutic agent in cancer but \[11C\] temozolomide is an investigational agent. In this research study, participants will receive standard treatment with bevacizumab and oral temozolomide as well as standard MRI scans. In addition, participants will undergo TMZ-PET scans before
Interventions
- DEVICE MRI-PET
- DEVICE TMZ-PET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2013-11 |
| Est. Completion | 2019-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01987830
The ClinicalTrials.gov registry entry for NCT01987830 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MRI-PET is the first listed.
NCT01987830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01987830 about?
NCT01987830 is a clinical study titled "Bevacizumab w / Temozolomide PET & Vascular MRI For GBM". This research study is exploring how the blood vessels in the participant's tumor change from treatment with bevacizumab, and how these changes affect the way their tumor absorbs temozolomide (TMZ). The pilot part of this study is to evaluate the use of \[11C\] temozolomide PET (TMZ-PET) scans and ...
What is the current status of trial NCT01987830?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2013-11. Estimated completion is 2019-04.
What interventions are being tested in trial NCT01987830?
The interventions under investigation include: MRI-PET (DEVICE), TMZ-PET (DEVICE).
Who is sponsoring clinical trial NCT01987830?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.